Asthmatics benefit from daily tiotropium

Adding tiotropium to standard therapy can delay exacerbations and improve airflow obstruction in patients with poorly controlled asthma, two randomised trials find.

Although rarely used in asthma, the long-acting bronchodilator was found to prolong time to first exacerbation by 56 days compared to placebo, in twin trials involving a total of 912 adults. 

Once-daily tiotropium also improved airflow obstruction over 24 hours, and spirometric measures such as peak FEV1 over the 48-week